Atea Pharmaceuticals (AVIR) Free Cash Flow (2019 - 2026)

Atea Pharmaceuticals' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$46.4 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 51.79% year-over-year to -$46.4 million; the TTM figure through Mar 2026 stood at -$147.9 million (down 17.17% YoY), while the FY2025 annual figure was -$132.0 million, up 2.56% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$46.4 million, down from -$28.2 million in the prior quarter.
• The five-year high for Free Cash Flow was -$16.1 million in Q2 2023, with the low at -$59.1 million in Q1 2022.
• The 5-year median for Free Cash Flow is -$29.8 million (2023), against an average of -$30.7 million.
• Peak annual rise in Free Cash Flow reached 71.43% in 2022, while the deepest fall reached 250.73% in 2022.
• Atea Pharmaceuticals' Free Cash Flow stood at -$21.5 million in 2022, then declined by 1.34% to -$21.8 million in 2023, then sank by 39.22% to -$30.4 million in 2024, then gained by 7.15% to -$28.2 million in 2025, then slumped by 64.37% to -$46.4 million in 2026.
• Business Quant data shows AVIR's Free Cash Flow at -$46.4 million in Q1 2026, -$28.2 million in Q4 2025, and -$40.4 million in Q3 2025.